Current Ratio
10.78x
Period-end balance · Through 31 Mar 2024
YoY relative change: -75%
MERRIMACK PHARMACEUTICALS INC financial metrics
Period Q1 2024 · Filed 15 May 2024
Key metrics snapshot
Debt-to-equity
0.09x
Period-end balance · Through 31 Mar 2024
YoY relative change: +190%
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
10.78x
Period-end balance · 31 Mar 2024
|
-75% |
| Debt-to-equity |
0.09x
Period-end balance · 31 Mar 2024
|
+190% |
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
14,531,760
Period-end balance · 15 Mar 2024
|
+1.9% |
| Common Stock, Shares, Outstanding |
14,532,000
Period-end balance · 31 Mar 2024
|
+1.9% |
| Common Stock, Value, Issued |
$1,345,000
Period-end balance · 31 Mar 2024
|
+0.15% |
| Weighted Average Number of Shares Outstanding, Basic |
14,452,000
Reported period · 31 Mar 2024
|
+1.4% |
| Weighted Average Number of Shares Outstanding, Diluted |
14,452,000
Reported period · 31 Mar 2024
|
+1.4% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$168,000
Period-end balance · 31 Mar 2024
|
+89% |
| Accrued Liabilities, Current |
$161,000
Period-end balance · 31 Mar 2024
|
+18% |
| Assets |
$244,322,000
Period-end balance · 31 Mar 2024
|
+1144% |
| Assets, Current |
$244,319,000
Period-end balance · 31 Mar 2024
|
+1145% |
| Cash and Cash Equivalents, at Carrying Value |
$234,160,000
Period-end balance · 31 Mar 2024
|
+1107% |
| Cash, Cash Equivalents, and Short-term Investments |
$244,100,000
Period-end balance · 31 Mar 2024
|
+1158% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$234,160,000
Period-end balance · 31 Mar 2024
|
+1107% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$228,171,000
Reported period · 31 Mar 2024
|
|
| Common Stock, Par or Stated Value Per Share |
0.01
Period-end balance · 31 Mar 2024
|
0% |
| Common Stock, Shares Authorized |
30,000,000
Period-end balance · 31 Mar 2024
|
0% |
| Common Stock, Shares, Issued |
14,532,000
Period-end balance · 31 Mar 2024
|
+1.9% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
$200,460,000
Trailing 12 months · 31 Mar 2024
|
|
| Earnings Per Share, Basic |
14
Trailing 12 months · 31 Mar 2024
|
|
| Earnings Per Share, Diluted |
14
Trailing 12 months · 31 Mar 2024
|
|
| General and Administrative Expense |
$2,259,000
Trailing 12 months · 31 Mar 2024
|
+3.5% |
| Liabilities |
$22,672,000
Period-end balance · 31 Mar 2024
|
+4797% |
| Liabilities and Equity |
$244,322,000
Period-end balance · 31 Mar 2024
|
+1144% |
| Liabilities, Current |
$22,672,000
Period-end balance · 31 Mar 2024
|
+4797% |
| Net Cash Provided by (Used in) Financing Activities |
$1,485,000
Reported period · 31 Mar 2024
|
+730% |
| Net Cash Provided by (Used in) Investing Activities |
$228,000,000
Reported period · 31 Mar 2024
|
+163929% |
| Net Cash Provided by (Used in) Operating Activities |
-$1,314,000
Reported period · 31 Mar 2024
|
-269% |
| Nonoperating Income (Expense) |
$925,000
Trailing 12 months · 31 Mar 2024
|
+32% |
| Operating Income (Loss) |
-$2,259,000
Trailing 12 months · 31 Mar 2024
|
-11% |
| Other Assets, Noncurrent |
$3,000
Period-end balance · 31 Mar 2024
|
-57% |
| Preferred Stock, Par or Stated Value Per Share |
0.01
Period-end balance · 31 Mar 2024
|
0% |
| Preferred Stock, Shares Authorized |
10,000,000
Period-end balance · 31 Mar 2024
|
0% |
| Preferred Stock, Shares Issued |
0
Period-end balance · 31 Mar 2024
|
|
| Preferred Stock, Shares Outstanding |
0
Period-end balance · 31 Mar 2024
|
|
| Retained Earnings (Accumulated Deficit) |
-$347,447,000
Period-end balance · 31 Mar 2024
|
+37% |
| Stockholders' Equity Attributable to Parent |
$221,650,000
Period-end balance · 31 Mar 2024
|
+1056% |
Comparisons, sources and research notes
Sources and sharing
MERRIMACK PHARMACEUTICALS INC Financial Facts
- Context
- Latest metrics period: Q1 2024
- Latest reported value
- Current Ratio 10.78x
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q1 2024
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q1 2024.
- Most recent SEC facts end date on this page: 31 Mar 2024.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for MERRIMACK PHARMACEUTICALS INC
Latest financial period: Q1 2024. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
15 May 2024
Page type
Company facts
Latest period
Q1 2024
SEC-backed company facts were refreshed from filings filed on 15 May 2024.
Benchmark Context
How Current Ratio compares
Current Ratio is down about 75% versus the comparable prior period.
Compared with
Compared with MERRIMACK PHARMACEUTICALS INC's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q1 2024.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
Filing notes and source
Key facts
- MERRIMACK PHARMACEUTICALS INC financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q1 2024.
- Headline metric: Current Ratio 10.78x.
Change
- Current Ratio YoY relative change: -75%.
- Most recent SEC facts end date: 31 Mar 2024.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2024-03-31) highlights Current Ratio 10.78x and Debt-to-equity 0.09x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -2,480,000.0 USD · through 2024-03-31 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Capital expenditures: unavailable on a verified comparable basis
- Cash and equivalents: 244,100,000.0 USD · through 2024-03-31 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Free cash flow unavailable: matching usd annual or trailing-12-month operating cash flow and cash capex are required
- Debt unavailable: no complete usd debt balance at the latest balance date
- Ticker missing for issuer
- Valuation unavailable: free cash flow is missing
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
55.6/100
Caution Confidence low
Financial Health
- Current Ratio
- 10.78x
- Debt to Equity
- 0.09x
Strengths
Debt-to-equity
Watchpoints
Current Ratio
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first